Header Logo

Connection

MURALI CHINTAGUMPALA to Medulloblastoma

Back to Details
This is a "connection" page, showing publications MURALI CHINTAGUMPALA has written about Medulloblastoma.
MURALI CHINTAGUMPALA
Connection Strength
7.355
Medulloblastoma
  1. Overall survival and secondary malignant neoplasms in children receiving passively scattered proton or photon craniospinal irradiation for medulloblastoma. Cancer. 2021 Oct 15; 127(20):3865-3871.
    View in: PubMed
    Score: 0.586
  2. Hypothyroidism after craniospinal irradiation with proton or photon therapy in patients with medulloblastoma. Pediatr Hematol Oncol. 2018 May; 35(4):257-267.
    View in: PubMed
    Score: 0.490
  3. Ototoxicity and cochlear sparing in children with medulloblastoma: Proton vs. photon radiotherapy. Radiother Oncol. 2018 07; 128(1):128-132.
    View in: PubMed
    Score: 0.460
  4. Local control after craniospinal irradiation, intensity-modulated radiotherapy boost, and chemotherapy in childhood medulloblastoma. Cancer. 2011 Feb 01; 117(3):635-41.
    View in: PubMed
    Score: 0.277
  5. Ototoxicity after intensity-modulated radiation therapy and cisplatin-based chemotherapy in children with medulloblastoma. Int J Radiat Oncol Biol Phys. 2010 Dec 01; 78(5):1445-50.
    View in: PubMed
    Score: 0.267
  6. Changes mimicking new leptomeningeal disease after intensity-modulated radiotherapy for medulloblastoma. Int J Radiat Oncol Biol Phys. 2009 Jan 01; 73(1):214-21.
    View in: PubMed
    Score: 0.235
  7. The cochlear dose and the age at radiotherapy predict severe hearing loss after passive scattering proton therapy and cisplatin in children with medulloblastoma. Neuro Oncol. 2024 Oct 03; 26(10):1912-1920.
    View in: PubMed
    Score: 0.183
  8. A Case Series of Children With Medulloblastoma Depicting the Disparities in Care and the Challenges in the Detection and Treatment of Pediatric Central Nervous System Tumors in Low-Resource Settings: A Case Study of Uganda. Pediatr Neurol. 2024 Dec; 161:67-72.
    View in: PubMed
    Score: 0.182
  9. Late-onset lymphopenia during radiation is associated with an increased risk of tumor recurrence in newly diagnosed pediatric medulloblastoma. Pediatr Blood Cancer. 2024 Jul; 71(7):e31022.
    View in: PubMed
    Score: 0.178
  10. Adaptive, behavioral, and emotional outcomes following postoperative pediatric cerebellar mutism syndrome in survivors treated for medulloblastoma. J Neurosurg Pediatr. 2024 Jun 01; 33(6):516-523.
    View in: PubMed
    Score: 0.177
  11. Proton Therapy Mediates Dose Reductions to Brain Structures Associated With Cognition in Children With Medulloblastoma. Int J Radiat Oncol Biol Phys. 2024 May 01; 119(1):200-207.
    View in: PubMed
    Score: 0.173
  12. Cerebellar Mutism Syndrome in Pediatric Neuro-oncology: A Multidisciplinary Perspective and Call for Research Priorities. Pediatr Neurol. 2022 07; 132:4-10.
    View in: PubMed
    Score: 0.155
  13. Serial assessment of measurable residual disease in medulloblastoma liquid biopsies. Cancer Cell. 2021 11 08; 39(11):1519-1530.e4.
    View in: PubMed
    Score: 0.149
  14. Comparison of hypothyroidism, growth hormone deficiency, and adrenal insufficiency following proton and photon radiotherapy in children with medulloblastoma. J Neurooncol. 2021 Oct; 155(1):93-100.
    View in: PubMed
    Score: 0.149
  15. Treatment controversies in medulloblastoma. Curr Opin Oncol. 2001 May; 13(3):154-9.
    View in: PubMed
    Score: 0.145
  16. Observed-to-expected incidence ratios of second malignant neoplasms after radiation therapy for medulloblastoma: A Surveillance, Epidemiology, and End Results analysis. Cancer. 2021 07 01; 127(13):2368-2375.
    View in: PubMed
    Score: 0.143
  17. Scoliosis in Children Treated With Photon Craniospinal Irradiation for Medulloblastoma. Int J Radiat Oncol Biol Phys. 2021 03 01; 109(3):712-717.
    View in: PubMed
    Score: 0.143
  18. Clinical Outcomes and Patient-Matched Molecular Composition of Relapsed Medulloblastoma. J Clin Oncol. 2021 03 01; 39(7):807-821.
    View in: PubMed
    Score: 0.142
  19. Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03). J Clin Oncol. 2021 03 01; 39(7):822-835.
    View in: PubMed
    Score: 0.141
  20. Development of second primary tumors and outcomes in medulloblastoma by treatment modality: A Surveillance, Epidemiology, and End Results analysis. Pediatr Blood Cancer. 2020 08; 67(8):e28373.
    View in: PubMed
    Score: 0.136
  21. Reply to S.A. Milgrom et al. J Clin Oncol. 2020 07 01; 38(19):2212-2213.
    View in: PubMed
    Score: 0.135
  22. Germline Elongator mutations in Sonic Hedgehog medulloblastoma. Nature. 2020 04; 580(7803):396-401.
    View in: PubMed
    Score: 0.134
  23. Superior Intellectual Outcomes After Proton Radiotherapy Compared With Photon Radiotherapy for Pediatric Medulloblastoma. J Clin Oncol. 2020 02 10; 38(5):454-461.
    View in: PubMed
    Score: 0.131
  24. Germline POLE mutation in a child with hypermutated medulloblastoma and features of constitutional mismatch repair deficiency. Cold Spring Harb Mol Case Stud. 2019 10; 5(5).
    View in: PubMed
    Score: 0.130
  25. Germline GPR161 Mutations Predispose to Pediatric Medulloblastoma. J Clin Oncol. 2020 01 01; 38(1):43-50.
    View in: PubMed
    Score: 0.130
  26. Pilot study of DNA methylation-derived neutrophil-to-lymphocyte ratio and survival in pediatric medulloblastoma. Cancer Epidemiol. 2019 04; 59:71-74.
    View in: PubMed
    Score: 0.124
  27. Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort. Lancet Oncol. 2018 06; 19(6):785-798.
    View in: PubMed
    Score: 0.118
  28. Meta-analysis of the incidence and patterns of second neoplasms after photon craniospinal irradiation in children with medulloblastoma. Pediatr Blood Cancer. 2018 08; 65(8):e27095.
    View in: PubMed
    Score: 0.117
  29. DNA methylation of a novel PAK4 locus influences ototoxicity susceptibility following cisplatin and radiation therapy for pediatric embryonal tumors. Neuro Oncol. 2017 Oct 01; 19(10):1372-1379.
    View in: PubMed
    Score: 0.113
  30. Exploratory analysis of ERCC2 DNA methylation in survival among pediatric medulloblastoma patients. Cancer Epidemiol. 2016 10; 44:161-166.
    View in: PubMed
    Score: 0.105
  31. Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog-Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032. J Clin Oncol. 2015 Aug 20; 33(24):2646-54.
    View in: PubMed
    Score: 0.097
  32. Therapeutic implications of CD1d expression and tumor-infiltrating macrophages in pediatric medulloblastomas. J Neurooncol. 2014 Nov; 120(2):293-301.
    View in: PubMed
    Score: 0.091
  33. Secondary glioblastoma multiform in a patient with CHARGE syndrome and prior radiation therapy for medulloblastoma. Pediatr Hematol Oncol. 2014 May; 31(4):366-8.
    View in: PubMed
    Score: 0.088
  34. Evaluation of amifostine for protection against cisplatin-induced serious hearing loss in children treated for average-risk or high-risk medulloblastoma. Neuro Oncol. 2014 Jun; 16(6):848-55.
    View in: PubMed
    Score: 0.087
  35. Concordance between the chang and the International Society of Pediatric Oncology (SIOP) ototoxicity grading scales in patients treated with cisplatin for medulloblastoma. Pediatr Blood Cancer. 2014 Apr; 61(4):601-5.
    View in: PubMed
    Score: 0.086
  36. Phase I study of vismodegib in children with recurrent or refractory medulloblastoma: a pediatric brain tumor consortium study. Clin Cancer Res. 2013 Nov 15; 19(22):6305-12.
    View in: PubMed
    Score: 0.085
  37. Implications of tumor location on subtypes of medulloblastoma. Pediatr Blood Cancer. 2013 Sep; 60(9):1408-10.
    View in: PubMed
    Score: 0.082
  38. Maternal variation in EPHX1, a xenobiotic metabolism gene, is associated with childhood medulloblastoma: an exploratory case-parent triad study. Pediatr Hematol Oncol. 2012 Nov; 29(8):679-85.
    View in: PubMed
    Score: 0.080
  39. Low early ototoxicity rates for pediatric medulloblastoma patients treated with proton radiotherapy. Radiat Oncol. 2011 Jun 02; 6:58.
    View in: PubMed
    Score: 0.073
  40. A single intravenous injection of oncolytic picornavirus SVV-001 eliminates medulloblastomas in primary tumor-based orthotopic xenograft mouse models. Neuro Oncol. 2011 Jan; 13(1):14-27.
    View in: PubMed
    Score: 0.070
  41. Medulloblastoma and juvenile pilocytic astrocytoma presenting as synchronous primary brain tumors in a child: case report. J Neurosurg Pediatr. 2010 Feb; 5(2):149-54.
    View in: PubMed
    Score: 0.066
  42. Low-level copy gain versus amplification of myc oncogenes in medulloblastoma: utility in predicting prognosis and survival. Laboratory investigation. J Neurosurg Pediatr. 2009 Jan; 3(1):61-5.
    View in: PubMed
    Score: 0.061
  43. Glutathione S-transferase M1 and T1 polymorphisms may predict adverse effects after therapy in children with medulloblastoma. Neuro Oncol. 2009 Jun; 11(3):292-300.
    View in: PubMed
    Score: 0.061
  44. Neuropsychological outcome following intensity-modulated radiation therapy for pediatric medulloblastoma. Pediatr Blood Cancer. 2008 Aug; 51(2):275-9.
    View in: PubMed
    Score: 0.060
  45. Amifostine protects against cisplatin-induced ototoxicity in children with average-risk medulloblastoma. J Clin Oncol. 2008 Aug 01; 26(22):3749-55.
    View in: PubMed
    Score: 0.060
  46. Direct orthotopic transplantation of fresh surgical specimen preserves CD133+ tumor cells in clinically relevant mouse models of medulloblastoma and glioma. Stem Cells. 2008 Jun; 26(6):1414-24.
    View in: PubMed
    Score: 0.058
  47. Multi-institution prospective trial of reduced-dose craniospinal irradiation (23.4 Gy) followed by conformal posterior fossa (36 Gy) and primary site irradiation (55.8 Gy) and dose-intensive chemotherapy for average-risk medulloblastoma. Int J Radiat Oncol Biol Phys. 2008 Mar 01; 70(3):782-7.
    View in: PubMed
    Score: 0.056
  48. FOXG1 dysregulation is a frequent event in medulloblastoma. J Neurooncol. 2007 Nov; 85(2):111-22.
    View in: PubMed
    Score: 0.055
  49. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. Lancet Oncol. 2006 Oct; 7(10):813-20.
    View in: PubMed
    Score: 0.053
  50. Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. J Clin Oncol. 2006 Apr 20; 24(12):1924-31.
    View in: PubMed
    Score: 0.051
  51. Neurocognitive consequences of risk-adapted therapy for childhood medulloblastoma. J Clin Oncol. 2005 Aug 20; 23(24):5511-9.
    View in: PubMed
    Score: 0.049
  52. Results of a phase II upfront window of pharmacokinetically guided topotecan in high-risk medulloblastoma and supratentorial primitive neuroectodermal tumor. J Clin Oncol. 2004 Aug 15; 22(16):3357-65.
    View in: PubMed
    Score: 0.045
  53. Clinical, histopathologic, and molecular markers of prognosis: toward a new disease risk stratification system for medulloblastoma. J Clin Oncol. 2004 Mar 15; 22(6):984-93.
    View in: PubMed
    Score: 0.044
  54. Intensity-modulated radiation therapy for pediatric medulloblastoma: early report on the reduction of ototoxicity. Int J Radiat Oncol Biol Phys. 2002 Mar 01; 52(3):599-605.
    View in: PubMed
    Score: 0.038
  55. White matter lesions detected by magnetic resonance imaging after radiotherapy and high-dose chemotherapy in children with medulloblastoma or primitive neuroectodermal tumor. J Clin Oncol. 2004 Nov 15; 22(22):4551-60.
    View in: PubMed
    Score: 0.012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.